WINNERS & LOSERS: US-China optimism supports miners; Syncona up
21st Sep 2026 10:32
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Monday. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Monday. Read More
Syncona Ltd - London-based life science investor - Portfolio holding Beacon Therapeutics Ltd's gene therapy laru-zova meets its primary endpoint in a phase II/III trial in treating the blinding condition X-linked retinitis pigmentosa. The endpoint, which was endorsed by the US Food & Drug Administration, was demonstrating statistically significant low luminesce visual acuity in patients at month 12, compared to a control group. XLRP is an inherited retinal disease that leads to progressive vision loss, moving from night blindness to being legally blind. Following the test results, Beacon plans a rolling biologics license application submission later this year. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by FTSE 250-listed London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Syncona Ltd on Thursday reported a flat annual performance for net asset value, with upside from Beacon Therapeutics PLC offset by write-downs elsewhere. Read More
Syncona Ltd - London-based investor in life science companies - Invests USD24.5 million in ophthalmic gene therapy company Beacon Therapeutics' USD75 million Series C financing. Says the financing round was oversubscribed and brings Beacon's total funding raised so far to approximately USD367 million. Beacon will use the proceeds "to progress commercialisation plans" and to complete the development of its lead programme laru-zova, "a potential best-in-class gene therapy" for X-linked retinitis pigmentosa, Syncona says. Syncona's holding value of Beacon will now be USD237.6 million, including new capital invested, and it will hold a 38.4% ownership stake. Read More
(Alliance News) - Syncona Ltd on Thursday reported a fall in its net asset value but said it is well-positioned to deliver value as market conditions in biotech improve. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Syncona Ltd - London-based investor in life science companies - Sets out results of its strategy review, proposing focus on realisations of mature private companies in its portfolio until it has been able to return up to GBP250 million to shareholders "in a timely manner". The returns, representing about 40% of the company's current market value, could take the form of a tender offer, share buyback, or special dividend, Syncona says. Read More
(Clarifying that Brent oil was trading higher early Tuesday, not lower.) Read More
(Alliance News) - Stock prices in London opened higher on Tuesday as investors digested fresh UK borrowing figures showing the government's finances remain under pressure, even as sentiment improved globally. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Syncona Ltd on Thursday said its net asset value increased during the first quarter of its financial year, citing strong clinical execution. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Correcting the UK annual retail sales growth for April.) Read More
(Correcting the UK public sector borrowing requirement for May.) Read More
(Alliance News) - The FTSE 100 was called in the green on Friday, while new UK labour market data has shown "modest growth" in new postings last month. Read More
(Corrects the pound sterling quote in light of the BoE rate call.) Read More
(Alliance News) - London stocks were mostly lower at midday on Thursday, after the Bank of England left its key rates unchanged at 4.25%. However, three Monetary Policy Committee members voted for a 25 basis point cut. Read More